Evidence map›Paper›PMID 38536511›Full record

ArticleEJNMMI research2024

Repeatability of

Mark Muzi, Lanell M Peterson, Jennifer M Specht, Daniel S Hippe, Alena Novakova-Jiresova, Jean H Lee, Brenda F Kurland, David A Mankoff, Nancy Obuchowski, Hannah M Linden and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Mark MuziDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA. muzi@uw.edu.ORCID http://orcid.org/0000-0002-8767-191X
Lanell M PetersonDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
Jennifer M SpechtDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
Daniel S HippeDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
Alena Novakova-JiresovaThomayer University Hospital, Prague, Czech Republic.
Jean H LeeDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
Brenda F KurlandDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
David A MankoffUniversity of Pennsylvania, Philadelphia, PA, USA.
Nancy ObuchowskiCleveland Clinic, Cleveland, OH, USA.
Hannah M LindenDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
Paul E KinahanDepartment of Radiology, University of Washington Medical Center, 1959 NE Pacific Street, UW Box 356465, Seattle, Washington, 98195, USA.
University of Washington Medical Center · USCleveland Clinic · USThomayer University Hospital · CZUniversity of Pennsylvania · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Advanced PET/CT Imaging for Improving Clinical TrialsU01CA148131 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., LINDEN, HANNAH M · 2010 to 2019
$6.0M
Core Laboratory for Advanced PET and MRI image analysisR50CA211270 · NCI · UNIVERSITY OF WASHINGTON · PI Mark Muzi · 2017 to 2026
$2.6M
PET to Measure Breast Cancer Bone Metastasis ResponseR01CA124573 · NCI · UNIVERSITY OF WASHINGTON · PI SPECHT, JENNIFER MARIE · 2007 to 2011
$1.8M
NCI NIH HHS P30 CA015704NCI NIH HHS P30-CA015704NCI NIH HHS R01 CA124573NCI NIH HHS R01-CA124573NCI NIH HHS R50 CA211270NCI NIH HHS R50-CA211270NCI NIH HHS U01 CA148131NCI NIH HHS U01-CA148131
6 · The paper itself

Abstract

backgroundStandard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (

methodsFor this study, nine patients with 38 bone lesions were imaged with

resultsThe mean relative difference of SUVmax and SULpeak in 38 bone tumors of the first cohort were 4.3% and 6.7%. The upper and lower asymmetric limits of the repeatability coefficient were 19.4% and - 16.3% for SUVmax, and 21.2% and - 17.5% for SULpeak.

conclusionIn evaluating bone tumor response for breast cancer patients with bone-dominant metastases using

Indexed as

18F-FDG PETBone metastasesBreast cancerRepeatabilityTest-retest

Identifiers

PMID38536511
PMCPMC10973316
OpenAlexW4393234354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.